Highlights

  • Holista Colltech faces a defining test as its latest strategy develops.
  • The legal settlement closes a chapter, but Liquidity and collagen Investment remain major tests.
  • The latest financial figures show why execution matters for HCT investors.
  • Investors must weigh the next milestones against funding and operating risks.

Holista Colltech (ASX:HCT) has put a long-running legal dispute behind it, but at a cost. The Western Australian company settled the ProImmune litigation for US$1.8 million, and the final payment on 10 July 2026 closed the matter while leaving its Balance Sheet thinner and its Going Concern warning in place.

A small supplements Business with collagen ambitions

The company describes Holista as a bio-industrial company developing food ingredients and ovine collagen for cosmetic and biomedical uses. In practice, most Revenue comes from dietary supplements.

In the half-year to 30 June 2026, group revenue was A$2.99 million, up 3.6 per cent from A$2.89 million.

Management also said it had resolved a legacy returns issue in the division, which produced a favourable A$128,000 refund Liability adjustment, and had strengthened its sales and Marketing team.

What the ProImmune settlement did to the accounts

A Supreme Court of Western Australia judgment in April 2026 had enforced a Debt of US$2,063,141.

It paid US$1.0 million on 22 April 2026 and US$0.8 million on 10 July. The half-year net loss was A$2.56 million, against A$0.30 million a year earlier, and the company says one-off settlement costs of about A$2.66 million explain the swing, leaving an Underlying Profit of roughly A$0.095 million.

Cash and funding

Cash fell to A$564,563 at 30 June 2026 from A$2.16 million at 31 December 2025, and operating cash outflow for the half was A$1.44 million. Net liabilities were A$2.98 million and the Working Capital deficiency was A$3.32 million.

The June quarter report showed customer receipts of about A$1.48 million, up 12.9 per cent on the prior quarter, and operating outflow of A$1.29 million, mostly because of the first settlement payment. It put total available funding, including unused facilities, at A$1.97 million, or 1.53 quarters.

To fund the settlement, Holista signed a term sheet on 9 July 2026 for an unsecured A$370,724 convertible Loan from Powerwind Plantation Sdn Bhd. Interest is 8 per cent a year, conversion would be at A$0.07 a share for 5,296,055 shares at the lender's election, and Shareholder approval is required.

Collagen joint venture and other projects

The partner contributed RM5.0 million, which allowed the venture to buy land in Collie, Western Australia, for a proposed Manufacturing facility.

Collagen revenue is still tiny at A$28,781 for the half. Food ingredients fell to A$29,963 from A$204,889 because a customer is being privatised, and the company is developing a sugar-free formulation. Infection control and agriculture products, including a nano urea fertiliser and a poultry probiotic, contributed A$23,484 as they move out of trials.

Risks and what to watch

The first risk is liquidity: with limited cash and a working capital deficiency, Holista depends on facilities, lender support and the convertible loan being approved. Conversion would also create new shares.

The second is concentration, since a single supplements division generates nearly all income and relies on online sales channels and the planned 25th anniversary push for the Pristin brand.

Collagen is a longer-dated opportunity, still at an early commercial stage, that depends on building the Collie Facility and winning customers.